• Please log in or register to access this feature.

Original Article

You have full text access to this OnlineOpen article

Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial†

  1. Lee E. Moore PhD1,‡,*,
  2. Ruth M. Pfeiffer PhD1,
  3. Zhen Zhang PhD2,
  4. Karen H. Lu MD3,
  5. Eric T. Fung MD4,
  6. Robert C. Bast Jr. MD5

Article first published online: 29 JUN 2011

DOI: 10.1002/cncr.26241

Issue

Cancer

Cancer

Volume 118, Issue 1, pages 91–100, 1 January 2012

Additional Information

How to Cite

Moore, L. E., Pfeiffer, R. M., Zhang, Z., Lu, K. H., Fung, E. T. and Bast, R. C. (2012), Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Cancer, 118: 91–100. doi: 10.1002/cncr.26241

Author Information

  1. 1

    Occupational and Environmental Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

  2. 2

    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland

  3. 3

    Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas

  4. 4

    Vermillion, Inc., Fremont, California

  5. 5

    Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas

  1. ‡

    Fax: (301) 402-1819

*Occupational and Environmental Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD 20852-7240

  1. †

    The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations suggest endorsement by the US Government.

  2. ‡

    Fax: (301) 402-1819

Publication History

  1. Issue published online: 16 DEC 2011
  2. Article first published online: 29 JUN 2011
  3. Manuscript Accepted: 11 APR 2011
  4. Manuscript Revised: 8 APR 2011
  5. Manuscript Received: 14 DEC 2010

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (153K)

REFERENCES

  • 1
    Cannistra SA. Cancer of the ovary. N Engl J Med. 2004; 351: 2519-2529.
  • 2
    Buys SS, Partridge E, Greene MH, et al. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol. 2005; 193: 1630-1639.
  • 3
    Kim G, Minig L, Kohn EC. Proteomic profiling in ovarian cancer. Int J Gynecol Cancer. 2009; 19: S2-S6.
  • 4
    Zhang Z, Bast RC Jr, Yu Y, et al. Three biomarkers identified detection of early stage ovarian cancer. Cancer Res. 2004; 64: 5882-5890.
  • 5
    Hodgall E, Fung ET, Zhang Z, et al. Prospective independent validation of a marker panel for distinguishing malignant from benign pelvic masses: proceedings of the 39th Annual Meeting of the Society of Gynecologic Oncologists [abstract]. Gynecol Oncol. 2008; 108( suppl 2).
  • 6
    Moore LE, Fung ET, McGuire M, et al. Evaluation of apolipoprotein A1 and postranslationally modified forms of transthyretin as biomarkers for ovarian cancer detection in an independent study population. Cancer Epidemiol Biomarkers Prev. 2006; 15: 1641-1646.
  • 7
    Clarke CH, Fung ET, Yip C, et al. Use of a panel of proteomic markers to improve the sensitivity of CA125 for detecting stage I epithelial ovarian cancer [abstract]. J Clin Oncol. 2008; 26( May 20 suppl). Abstract 5542.
  • 8
    Zhu CS, Pinsky PF, Cramer DW, et al; for the PLCO Project Team. A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. Cancer Prev Res. 2011; 4: 375-383.
  • 9
    Cramer DW, Bast RC Jr, Berg CD, et al. Ovarian cancer biomarker performance in Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial specimens. Cancer Prev Res. 2011; 4: 365-374.
  • 10
    Fung ET, Yip TT, Lomas L, et al. Classification of cancer types by measuring variants of host response proteins using SELDI serum assays, Int J Cancer. 2005; 115: 783-789.
    Direct Link:
  • 11
    Hand DJ. Discrimination and Classification. NY: John Wiley & Sons, Inc.; 1981.
  • 12
    SAS Institute, Inc. SAS Users Guide, Version 9. Cary, NC: SAS Institute, Inc.; 1999.
  • 13
    Breiman L, Spector P. Submodel selection and evaluation in regression. The X-random case. Int Stat Rev. 1992; 60: 291-319.
  • 14
    Fisher RA. The use of multiple measurements in taxonomic problems. Ann Eugenics. 1950; 1936: 179-188.
  • 15
    Bast RC Jr, Klug TL, St John E, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983; 309: 883-887.
  • 16
    Bast RC Jr, Siegal FP, Runowicz C, et al. Elevation of serum CA125 prior to diagnosis of an epithelial ovarian carcinoma. Gynecol Oncol. 1985; 22: 115-120.
  • 17
    Skates SJ, Xu FJ, Yu YH, et al. Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer. 1995; 76( 10 suppl): 2004-2010.
    Direct Link:
  • 18
    Menon U, Gentry-Maharaj A, Hallett R, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009; 10: 327-340.
  • 19
    Lu KH, Skates S, Bevers T, et al. A prospective US ovarian cancer screening study using the risk of ovarian cancer algorithm (ROCA) [abstract]. Proc Am Soc Clin Oncol. 2010; 28: 390s. Abstract 5003.
  • 20
    Yurkovetsky Z, Lomakin A, Skates S, et al. Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol. 2010; 28: 2159-2166.
View Full Article (HTML) Get PDF (153K)